Related Experiment Videos
Efficacy of erythropoietin in premature infants
Adnan A Amin1, Daifulah M Alzahrani
1Department of Pediatrics, Neonatal Intensive Care Unit, Al-Hada Military Hospital, Taif, Kingdom of Saudi Arabia. adnamn@hotmail.com
Insights
Early administration of recombinant human erythropoietin and iron did not reduce blood transfusions in premature infants. Strict transfusion protocols may be more effective in minimizing transfusion needs for these vulnerable infants.
Area of Science:
- Neonatal Medicine
- Pediatric Hematology
Background:
- Premature infants, especially those with very low birth weight, often require blood transfusions due to anemia.
- Early interventions aim to reduce transfusion dependency in this high-risk population.
Purpose of the Study:
- To evaluate the impact of early intravenous recombinant human erythropoietin and iron on blood transfusion requirements in very low birth weight infants.
- To compare transfusion needs between infants receiving early erythropoietin/iron and those receiving conventional therapy.
Main Methods:
- A controlled clinical trial involving 20 very low birth weight infants (gestational age ~28.4 weeks, birth weight ~1031 gm).
- Infants were randomized to receive either recombinant human erythropoietin (200 U/kg/day) plus iron (1 mg/kg/day) or conventional care for 21 days.
- A strict protocol governed blood transfusion administration in the neonatal intensive care unit.
Main Results:
- Hemoglobin and hematocrit levels were comparable between the two groups throughout the 3-week study period.
- Reticulocyte counts were significantly higher in the erythropoietin-treated group on day 14.
- The number and volume of blood transfusions administered were similar in both the intervention and control groups.
Conclusions:
- Very low birth weight infants in this study received fewer blood transfusions than previously reported.
- Strict phlebotomy and transfusion criteria appear to be effective in minimizing the need for recombinant human erythropoietin in premature infants.
Objective:
To identify the effect of early parental recombinant human erythropoietin and iron administration on the blood transfusion requirement of premature infants.
Methods:
In a controlled clinical trial conducted at the neonatal intensive care unit of Al-Hada Military Hospital, Taif, Kingdom of Saudi Arabia over a 16 months period, we assigned 20 very low birth weight infants with gestational age of (mean +/- standard error of mean) 28.4 +/- 0.5 weeks and birth weight of (mean +/- standard error of mean) 1031 +/- 42 gm, to receive either intravenous recombinant human erythropoietin 200 U/kg/day and iron 1mg/kg/day or conventional therapy over a 21 day study period. Blood transfusion administration undergoes a strict protocol in our nursery.
Results:
During the 3 week study period, the hemoglobin and hematocrit remained similar in the 2 groups while the reticulocyte counts were greater in the recombinant human erythropoietin recipients on day 14. The number and volume of blood transfusions were similar in both groups.
Conclusion:
Very low birth weight infants receive fewer blood transfusions than the number previously reported. Strict phlebotomy and transfusion criteria could minimize the need for human recombinant erythropoietin.